China sales return to growth as Agilent's operating margin widens
Agilent's revenue rose 8.1 per cent as China sales returned to 9 per cent growth and adjusted operating margin reached 28.3 per cent. Insilico Medicine reported 106.3 million dollars of first-half revenue and roughly 7.3 billion dollars of announced deal value. Veeva's revenue grew 18 per cent to 928 million dollars with a 44.8 per cent adjusted operating margin. Life-sciences growth arrived through equipment, research partnerships and software.
Economics & Markets··Night
Agilent returns to growth in China
Agilent Technologies reported third-quarter revenue of 1.88 billion dollars, up 8.1 per cent from a year earlier. The laboratory-equipment maker's China sales returned to 9 per cent growth, while its non-GAAP operating margin expanded 320 basis points to 28.3 per cent, helped in part by tariff refunds. GAAP net income rose 8 per cent to 362 million dollars and diluted earnings reached 1.28 dollars a share. The company raised its full-year outlook to 7.49-7.51 billion dollars of revenue and 6.18-6.21 dollars in non-GAAP earnings per share. Renewed China growth and margin expansion arrived in the same quarter, with refunds remaining a separate support to the operating improvement.[1]
Insilico turns agreements into revenue
Insilico Medicine reported first-half revenue of 106.3 million dollars, up 287.2 per cent from a year earlier. Gross margin reached 90.3 per cent, with net profit of 35.54 million dollars and adjusted net profit of 51.23 million dollars. The company put the combined contract value of transactions announced in 2026 at roughly 7.3 billion dollars. Its Takeda collaboration is worth about 600 million dollars, including roughly 60 million dollars of upfront and near-term payments. A separate neuroimmune-disease research agreement with SK Biopharmaceuticals is valued at up to 2.5 billion dollars. Software-solutions revenue remained 2.70 million dollars, leaving drug discovery and development partnerships as the main source of growth.[2]
Veeva carries subscription growth at a high margin
Veeva Systems' revenue for the quarter ended 31 July rose 18 per cent from 789.1 million dollars a year earlier to 928.0 million dollars. Subscription revenue increased 16 per cent to 766.8 million dollars. The company reported operating income of 275.0 million dollars and a reported operating margin of 29.6 per cent; adjusted operating income was 415.9 million dollars and adjusted margin reached 44.8 per cent. Diluted earnings were 1.66 dollars a share on a reported basis and 2.35 dollars adjusted. Veeva guides full-year revenue to 3,682-3,687 million dollars and adjusted earnings to about 9.21 dollars a share. The result leaves subscriptions carrying most of the revenue base in life-sciences software.[3]
